昇興股份(002752.SZ)擬非公開發行不超1.67億股A股
格隆匯11月1日丨昇興股份(002752.SZ)公佈,公司本次非公開發行A股股票數量不超過本次發行前上市公司總股本8.33億股的20%,即1.67億股(含本數)。
本次非公開發行A股股票的發行對象為符合中國證監會規定的證券投資基金管理公司、證券公司、信託公司、財務公司、保險機構投資者、合格境外機構投資者,以及符合中國證監會規定的其他法人、自然人或者其他合格投資者,發行對象不超過10名。
募集資金總額不超過9.6億元,扣除發行費用後,本次發行募集資金淨額擬用於雲南曲靖灌裝及制罐生產線建設項目及昇興股份泉州分公司兩片罐制罐生產線技改增線項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.